SCHEMBL10116384

SCHEMBL10116384

CC(C)(C)S(=O)(=O)Nc1ccc(C(=O)Nc2cccc(OC3CCCCC3)c2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2 P00734 2/20 0.57
PLG P00747 2/20 0.57
PLAU P00749 2/20 0.57
PLAT P00750 2/20 0.57
PRSS1 P07477 2/20 0.57
KLKB1 P03952 1/20 0.57
HSD17B10 Q99714 1/20 0.47
PDE5A O76074 1/20 0.47
PDE1A P54750 1/20 0.47
PDE1B Q01064 1/20 0.47
PDE1C Q14123 1/20 0.47
KLK1 P06870 1/20 0.46
RAB9A P51151 6/20 0.46
SMN1; SMN2 Q16637 5/20 0.46
NPC1 O15118 5/20 0.46
ALDH1A1 P00352 4/20 0.46
KMT2A Q03164 2/20 0.46
TP53 P04637 1/20 0.46
PKM P14618 1/20 0.46
MAPT P10636 4/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10116415 0.99 F2 (0.58) F2PLGPLAUPLATPRSS1
SCHEMBL10116381 0.88 MAPT (0.52) RAB9ASMN1; SMN2NPC1ALDH1A1KMT2A
SCHEMBL10114615 0.87 LMNA (0.53) RAB9ASMN1; SMN2NPC1ALDH1A1KMT2A
SCHEMBL10116689 0.86 F2 (0.57) F2PLGPLAUPLATPRSS1
SCHEMBL10116718 0.84 F2 (0.58) F2PLGPLAUPLATPRSS1
SCHEMBL10116412 0.83 MAPT (0.47) F2PLGPLAUPLATPRSS1
SCHEMBL10116405 0.82 KCNK3 (0.65) SMN1; SMN2ALDH1A1LMNAHPGD
SCHEMBL10116388 0.82 NR1H4 (0.58) RAB9ASMN1; SMN2NPC1ALDH1A1KMT2A
SCHEMBL10116435 0.81 PDE4D (0.47) PDE5APDE1APDE1BPDE1CSMN1; SMN2
SCHEMBL13565296 0.80 HDAC4 (0.48) F2PLGPLAUPLATPRSS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8115027-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2012-02-14 US disclosed
US-8115027-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2012-02-14 US disclosed
US-20110039802-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2011-02-17 US disclosed
US-20100292500-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2010-11-18 US disclosed
US-20100292500-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2010-11-18 US disclosed
US-7781461-B2 NPY Y5 antagonist KAWANISHI YASUYUKI 2010-08-24 US disclosed
US-7781461-B2 NPY Y5 antagonist KAWANISHI YASUYUKI 2010-08-24 US disclosed
US-7265130-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2007-09-04 US disclosed
US-7265130-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2007-09-04 US disclosed
US-20070015762-A1 NPY Y5 antagonist KAWANISHI YASUYUKI 2007-01-18 US disclosed
US-20070015762-A1 NPY Y5 antagonist KAWANISHI YASUYUKI 2007-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015762-A1 NPY Y5 antagonist NPY5R, NPY1R, NPY2R F2 4595/4885PLG 4397/4885PLAU 3807/4885
US-20100292500-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R F2 4713/4885PLG 4448/4885PLAU 3968/4885
US-20110039802-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R F2 4612/4885PLG 4427/4885PLAU 3843/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.